The properties of the purified fibrinolytic principle from Agkistrodon acutus snake venom.
D000614:Aminocaproates / Q000494:pharmacology; D000818:Animals; D002118:Calcium / Q000494:pharmacology; D002364:Caseins / Q000378:metabolism; D003545:Cysteine / Q000494:pharmacology; D004492:Edetic Acid / Q000494:pharmacology; D005341:Fibrinolysin / Q000378:metabolism; D005342:Fibrinolysis / Q000187:drug effects*; D006470:Hemorrhage / Q000139:chemically induced; D006868:Hydrolysis; D066298:In Vitro Techniques; D008274:Magnesium / Q000494:pharmacology; D003012:Microbial Collagenase / Q000494:pharmacology; D012910:Snake Venoms / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D014357:Trypsin / Q000378:metabolism; D014361:Trypsin Inhibitors / Q000494:pharmacology; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism
D000614:Aminocaproates; D002364:Caseins; D012910:Snake Venoms; D014361:Trypsin Inhibitors; D004492:Edetic Acid; D014357:Trypsin; D005341:Fibrinolysin; D014568:Urokinase-Type Plasminogen Activator; D003012:Microbial Collagenase; D008274:Magnesium; D003545:Cysteine; D002118:Calcium